John Hood

9.6k total citations · 4 hit papers
56 papers, 7.2k citations indexed

About

John Hood is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, John Hood has authored 56 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 18 papers in Genetics and 17 papers in Hematology. Recurrent topics in John Hood's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Cell Adhesion Molecules Research (9 papers). John Hood is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Cell Adhesion Molecules Research (9 papers). John Hood collaborates with scholars based in United States, Italy and Germany. John Hood's co-authors include David A. Cheresh, Harris J. Granger, Marina Ziche, Ricardo F. Frausto, Cynthia J. Meininger, Brian P. Eliceiri, Jie Leng, Robert Paul, Pamela L. Schwartzberg and Mark D. Bednarski and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

John Hood

53 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of integrins in cell invasion and migration

2002 1.4k citations John Hood, David A. Cheresh profile →
Tumor Regression by Targeted Gene Delivery to the Neovasculature

2002 661 citations John Hood, Mark D. Bednarski et al. Science profile →
Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability

1999 646 citations Brian P. Eliceiri, Robert Paul et al. Molecular Cell profile →
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells

1998 575 citations John Hood, Marina Ziche et al. profile →

Peers

Countries citing papers authored by John Hood

Since Specialization

Citations

This map shows the geographic impact of John Hood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hood more than expected).

Fields of papers citing papers by John Hood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hood. The network helps show where John Hood may publish in the future.

Co-authorship network of co-authors of John Hood

This figure shows the co-authorship network connecting the top 25 collaborators of John Hood. A scholar is included among the top collaborators of John Hood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hood. John Hood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial 2025 ·The Lancet Respiratory Medicine ·Toby M. Maher, (unknown), John Hood, Jim Pitman, (unknown), Brian P. Hobbs, (unknown), Ivette Buendía-Roldán, Francis Thien, Jae W. Song, (unknown), Alicia Ramírez‐Rivera, A. DiFrancesco	0
2	Fedratinib in myelofibrosis 2020 ·Blood Advances ·Ann Mullally, John Hood, Claire Harrison, Ruben A. Mesa	60
3	A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee 2017 ·Osteoarthritis and Cartilage ·V. Deshmukh, (unknown), Charlene F. Barroga, Carine Bossard, S. KC, Luis Dellamary, Joshua D. Stewart, Kevin Chiu, Maureen Ibanez, M. Pedraza, T. Seo, Long Do, Steven Cho, (unknown), Betty Y. Tam, J. Tambiah, John Hood, Nancy E. Lane, Yusuf Yazıcı	176
4	Discovery of a small molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying treatment for knee osteoarthritis 2016 ·Osteoarthritis and Cartilage ·John Hood, V. Deshmukh, Charlene F. Barroga, (unknown)	7
5	Inhibitors of ABL and the ABL-T315I Mutation 2008 ·Current Topics in Medicinal Chemistry ·Glenn Noronha, Jianguo Cao, (unknown), Elena Dneprovskaia, Richard Fine, John Hood, Xinshan Kang, Boris Klebansky, (unknown), C. H. Mak, A. McPherson, Moorthy S. S. Palanki, Ved P. Pathak, (unknown), Richard Söll, (unknown)	34
6	Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors 2008 ·Cancer Cell ·Ifat Geron, Annelie Abrahamsson, Charlene F. Barroga, Edward Kavalerchik, Jason Gotlib, John Hood, Jeffrey A. Durocher, Chi Ching Mak, Glenn Noronha, Richard Söll, Ayalew Tefferi, K Kaushansky, Catriona Jamieson	104
7	Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors 2008 ·Cancer Cell ·Ifat Geron, Annelie Abrahamsson, Charlene F. Barroga, Edward Kavalerchik, Jason Gotlib, John Hood, Jeffrey A. Durocher, Chi Ching Mak, Glenn Noronha, Richard Söll, Ayalew Tefferi, K Kaushansky, Catriona Jamieson	1
8	A Dual VEGFR/JAK2 Kinase Inhibitor Suitable for Topical Delivery Inhibits Choroid Neovascularization in Mice 2007 ·Investigative Ophthalmology & Visual Science ·(unknown), C. H. Mak, (unknown), Daniel L. Lohse, Luis Dellamary, M. De Martin, John Hood, Glenn Noronha, John Doukas, Richard Söll	1
9	Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine) 2007 ·Drug Metabolism and Disposition ·Steven Hu, Richard Söll, Shiyin Yee, (unknown), Ahmed Kousba, (unknown), (unknown), A. McPherson, (unknown), Jianguo Cao, (unknown), John Hood, John Doukas, Glenn Noronha, Michael Martin	13
10	TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations 2007 ·Leukemia ·Animesh Pardanani, John Hood, Terra L. Lasho, Ross L. Levine, Michael Martin, Glenn Noronha, Christy M. Finke, Chi Ching Mak, Ruben A. Mesa, Huanzhang Zhu, Richard Söll, D. Gary Gilliland, Ayalew Tefferi	196
11	The design and preliminary structure–activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jianguo Cao, Richard Fine, (unknown), John Hood, Xinshan Kang, Boris Klebansky, (unknown), Chi Ching Mak, A. McPherson, Glenn Noronha, Moorthy S. S. Palanki, Ved P. Pathak, (unknown), Richard Söll, (unknown), Hong Zhu	21
12	Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury 2006 ·Proceedings of the National Academy of Sciences ·John Doukas, Wolfgang Wrasidlo, Glenn Noronha, Elena Dneprovskaia, Richard Fine, Sara M. Weis, John Hood, (unknown), Richard Söll, David A. Cheresh	108
13	Topically Applied Src Kinase/VEGFR Prodrug Reduces Retinal Vascular Permeability 2006 ·Investigative Ophthalmology & Visual Science ·Edith Aguilar, (unknown), Michael I. Dorrell, John Hood, Richard Söll, Shiyin Yee, Martin Friedlander	0
14	Tumor Regression by Targeted Gene Delivery to the Neovasculature breakdown → 2002 ·Science ·John Hood, Mark D. Bednarski, Ricardo F. Frausto, Samira Guccione, Ralph A. Reisfeld, Rong Xiang, David A. Cheresh	661
15	Induction of Angiogenesis by a Fragment of Human Tyrosyl-tRNA Synthetase 2002 ·Journal of Biological Chemistry ·Keisuke Wakasugi, Bonnie M. Slike, John Hood, Karla L. Ewalt, David A. Cheresh, Paul Schimmel	104
16	Targeted Delivery of Mutant Raf Kinase to Neovessels Causes Tumor Regression 2002 ·Cold Spring Harbor Symposia on Quantitative Biology ·John Hood, David A. Cheresh	11
17	Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability breakdown → 1999 ·Molecular Cell ·Brian P. Eliceiri, Robert Paul, Pamela L. Schwartzberg, John Hood, Jie Leng, David A. Cheresh	646
18	Nitric Oxide Is an Upstream Signal of Vascular Endothelial Growth Factor-induced Extracellular Signal-regulated Kinase½ Activation in Postcapillary Endothelium 1998 ·Journal of Biological Chemistry ·Astrid Parenti, Lucia Morbidelli, Xiao-Lan Cui, Janice G. Douglas, John Hood, Harris J. Granger, Fabrizio Ledda, Marina Ziche	377
19	A novel series of milbemycin antibiotics from Streptomyces strain E225. II. Isolation, characterization, structure elucidation and solution conformations. 1990 ·The Journal of Antibiotics ·(unknown), (unknown), Jeremy R. Everett, John Hood, (unknown)	25
20	A novel series of milbemycin antibiotics from Streptomyces strain E225. I. Discovery, fermentation and anthelmintic activity. 1989 ·The Journal of Antibiotics ·John Hood, (unknown), (unknown), (unknown), (unknown), (unknown)	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact